By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the…
By Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune…
By: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In…
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On October 27, the U.S. Food and Drug Administration approved toripalimab-tpzi (Loqtorzi) in combination…
By: Dr. Kanak Parmar On October 24, 2023 the U.S. Food and Drug Administration approved ivosidenib for adult patients with…
By Dr. Kanak Parmer Texas Tech University Health Sciences Center On October 16,2023 the U.S. Food and Drug Administration…
MARIPOSA-2: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal…
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in…
ESMO 2023 Update - KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author:…
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung…